Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical ...
Clinical Trials Arena on MSN
Pfizer’s obesity bet shows 14.1% weight loss in Phase IIb trial
"Pfizer’s obesity bet shows 14.1% weight loss in Phase IIb trial" was originally created and published by Clinical Trials ...
Life Sciences announced the publication “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient ...
Anavex Life Sciences Corp. announced that the Journal of Prevention of Alzheimer’s Disease published results from its Phase IIb/III study of blarcamesine (ANAVEX®2-73), an oral treatment for early ...
The sBLA is supported by data from the phase 3 CheckMate -76K trial which included 790 patients after complete resection of stage IIB or IIC melanoma. The Food and Drug Administration (FDA) has ...
The decision to stop the Phase IIb study was driven by “strategic business reasons,” according to a federal clinical trials ...
Hørsholm, Denmark-based Contera Pharma A/S’ lead asset for levodopa-induced dyskinesia in Parkinson’s disease, JM-010, failed to meet its primary endpoint in the late-stage phase IIb Astoria trial. JM ...
SINGAPORE, Sept. 29, 2025 /PRNewswire/ -- Xiaomi, one of the world's leading consumer electronics and smart manufacturing ...
The US imposed sanctions on the Russian-controlled International Investment Bank, saying its presence in Budapest allowed Moscow to expand its ability to spy, conduct “malign influence activities,” ...
Type IIb fast-twitch myofibers, known for their rapid contraction speed, are plentiful in small mammals but have largely ...
Type IIb fast-twitch myofibers, known for their rapid contraction speed, are plentiful in small mammals but have largely diminished in humans. Researchers at University of Tsukuba have discovered that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback